BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33912045)

  • 1. Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.
    Simoens S; Bento-Abreu A; Merckx B; Joubert S; Vermeersch S; Pavelyev A; Varga S; Morais E
    Front Pharmacol; 2021; 12():628434. PubMed ID: 33912045
    [No Abstract]   [Full Text] [Related]  

  • 2. Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong.
    Cheung TH; Cheng SSY; Hsu D; Wing-Lei Wong Q; Pavelyev A; Sukarom I; Saxena K
    Hum Vaccin Immunother; 2023 Aug; 19(2):2184605. PubMed ID: 37183965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong.
    Cheung TH; Cheng SSY; Hsu DC; Wong QW; Pavelyev A; Walia A; Saxena K; Prabhu VS
    Cost Eff Resour Alloc; 2021 Nov; 19(1):75. PubMed ID: 34801050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France.
    Majed L; Bresse X; El Mouaddin N; Schmidt A; Daniels VJ; Pavelyev A; Levy-Bachelot L; Elbasha E
    Vaccine; 2021 Jan; 39(2):438-446. PubMed ID: 33261895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health impact and cost effectiveness of implementing gender-neutral HPV vaccination in Japan.
    Palmer C; Tobe K; Negishi Y; You X; Chen YT; Abe M
    J Med Econ; 2023; 26(1):1546-1554. PubMed ID: 37962015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection.
    Choi W; Shim E
    Prev Med; 2024 Jan; 178():107743. PubMed ID: 37866695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
    De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
    Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom.
    Owusu-Edusei K; Palmer C; Ovcinnikova O; Favato G; Daniels V
    J Health Econ Outcomes Res; 2022; 9(1):140-150. PubMed ID: 35795155
    [No Abstract]   [Full Text] [Related]  

  • 10. The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
    Mahumud RA; Alam K; Dunn J; Gow J
    PLoS One; 2019; 14(10):e0223658. PubMed ID: 31596899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of nonavalent HPV vaccination in the Netherlands.
    Palmer C; Dolk C; Sabale U; Wang W; Saxena K
    Expert Rev Vaccines; 2024; 23(1):312-323. PubMed ID: 38417025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L; Rémy V; Oyee J; Largeron N
    Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Vaccine; 2020 Nov; 38(50):8032-8039. PubMed ID: 33121846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
    Chesson HW; Markowitz LE; Hariri S; Ekwueme DU; Saraiya M
    Hum Vaccin Immunother; 2016 Jun; 12(6):1363-72. PubMed ID: 26890978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
    Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A
    Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
    Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
    BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
    Boiron L; Joura E; Largeron N; Prager B; Uhart M
    BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia.
    Kosen S; Andrijono A; Ocviyanti D; Indriatmi W
    Asian Pac J Cancer Prev; 2017 Jul; 18(7):2011-2017. PubMed ID: 28749644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.